These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15515281)

  • 1. Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
    Colson K; Doss DS; Swift R; Tariman J; Thomas TE
    Clin J Oncol Nurs; 2004 Oct; 8(5):473-80. PubMed ID: 15515281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibition in cancer therapy.
    Smith GG
    J Infus Nurs; 2005; 28(4):258-64. PubMed ID: 16106209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding role of bortezomib in multiple myeloma: nursing implications.
    Colson K; Doss DS; Swift R; Tariman J
    Cancer Nurs; 2008; 31(3):239-49. PubMed ID: 18453881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
    Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M
    Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Kane RC; Farrell AT; Sridhara R; Pazdur R
    Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibition for treatment of multiple myeloma: clinical update.
    Stadtmauer EA
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib in multiple myeloma.
    Mateos MV; San Miguel JF
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practical update on the use of bortezomib in the management of multiple myeloma.
    San Miguel J; Bladé J; Boccadoro M; Cavenagh J; Glasmacher A; Jagannath S; Lonial S; Orlowski RZ; Sonneveld P; Ludwig H
    Oncologist; 2006 Jan; 11(1):51-61. PubMed ID: 16401713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
    Schwartz R; Davidson T
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib and its role in the management of patients with multiple myeloma.
    Orlowski RZ
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):171-9. PubMed ID: 15056047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
    Richardson P; Jagannath S; Colson K
    Clin Adv Hematol Oncol; 2006 May; 4(5):1; discussion 8; suppl 13. PubMed ID: 16830422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 study of bortezomib in relapsed, refractory myeloma.
    Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
    N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
    Prescrire Int; 2006 Jun; 15(83):98-100. PubMed ID: 16764098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic].
    Spicka I; Hájek R; Vytrasová M; Maisnar V; Gregora E; Schutzova M; Straub J; Scudla V; Adam Z; Klener P
    Cas Lek Cesk; 2005; 144(9):636, 638-40. PubMed ID: 16193944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical updates and nursing considerations for patients with multiple myeloma.
    Faiman B
    Clin J Oncol Nurs; 2007 Dec; 11(6):831-40. PubMed ID: 18063542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
    Jackson G; Einsele H; Moreau P; Miguel JS
    Cancer Treat Rev; 2005 Dec; 31(8):591-602. PubMed ID: 16298074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.